NCT01304147View on ClinicalTrials.gov

Intranasal Ketamine in Treatment-Resistant Depression

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

Ketamine

A single dose of intranasal ketamine up to 50 mg

DRUG

placebo

Single dose of saline intranasal

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

James Murrough

OTHER

NCT01304147 - Intranasal Ketamine in Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter